"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
Keep Reading →
August 27 - News
We maintain a database of quarterly 13F filings from hundreds of hedge funds and other notable investors.
Keep Reading →
August 27 - Hedge Funds
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 25 - News
The biotech industry is a marvel among traders and investors because it can double your investment, or halve it, based on a single clinical study.
Keep Reading →
August 25 - News
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Keep Reading →
August 23 - News
HIV, the virus that causes AIDS, has become one of the world's most devastating diseases since it was first recognized more than three decades ago.
Keep Reading →
August 23 - News
For a subgroup of the patients, the hazard ratio for overall survival in late-stage pancreatic cancer patients taking Incyte Corporation (NASDAQ:INCY)'s Jakafi and Roche's Xeloda...
Keep Reading →
August 23 - News
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
August 22 - News
About 15,680 Americans are diagnosed with chronic lymphocytic leukemia, or CLL, and approximately 5,000 new cases of mantle cell lymphoma, or MCL, occur in the U.S.
Keep Reading →
August 21 - News
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Keep Reading →
August 21 - News
Ignore the bickering between shareholders of Sarepta Therapeutics Inc (NASDAQ:SRPT) and GlaxoSmithKline plc (ADR) (NYSE:GSK) /Prosensa for a moment, because these are exciting...
Keep Reading →
August 20 - News
If you've ever taken the time to really follow the biopharmaceutical sector, you know very well that failures are a dime a dozen, and success stories are few and far between.
Keep Reading →
August 19 - News
This could have been an enormously more difficult effort. I started out with the goal to identify the three best stocks in health care to buy and hold for years, even decades.
Keep Reading →
August 19 - News
At least the Food and Drug Administration is polite.
Keep Reading →
August 19 - News
Both ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Aegerion Pharmaceuticals, Inc.
Keep Reading →
August 5 - News
High yields aren't everything when you're searching for the perfect dividend stock.
Keep Reading →
August 1 - News
Cystic fibrosis (CF), a genetic disorder that affects the lungs, the pancreas, liver, and intestine, is the second most common inherited disorder in the United States, after sickle...
Keep Reading →
August 1 - News
We are in the midst of the earnings season, my favorite time of the year.
Keep Reading →
July 29 - News
Gilead Sciences, Inc. (NASDAQ:GILD)' shares surged over 5% in after-hours trading on Thursday after the company announced its second-quarter earnings before giving up some of...
Keep Reading →
July 29 - News
It's easy to forget that AbbVie Inc (NYSE:ABBV) is technically only seven-months old.
Keep Reading →
July 29 - News
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
July 26 - News
Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered...
Keep Reading →
July 25 - News
AbbVie Inc (NYSE:ABBV) will release its quarterly report on Friday, and with its stock having jumped considerably since it started trading as a separate entity, investors are ...
Keep Reading →
July 24 - News
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Keep Reading →
July 24 - News
For nearly two decades, investment pro Ken Fisher's stock picks have outperformed the overall market.
Keep Reading →
July 23 - News
Today, let's look at Fisher Asset Management, founded in 1979 by Ken Fisher.
Keep Reading →
July 23 - Hedge Funds
According to multiple reports , Harvard researchers Timothy Henrich and Daniel Kuritzkes have recently noted a surprising side-effect to cancer treatments performed on two separate...
Keep Reading →
July 22 - News
You may or may not have heard, but it's earnings season again.
Keep Reading →
July 22 - News
The biotech industry is a cutthroat one, with companies constantly racing to get new treatments approved by the FDA ahead of their rivals.
Keep Reading →
July 22 - News
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Keep Reading →
July 19 - News
The upcoming all-oral hepatitis C treatments earned well-deserved attention for some staggering cure rates, particularly in patient groups who haven’t responded well to the ...
Keep Reading →
July 11 - News
It’s been a healthy year-to-date for the biotech sector, with the space logging huge gains above and beyond those of the broad based market.
Keep Reading →
July 10 - News
Hepatitis C, caused by the hepatitis C virus (HCV), is an infectious disease affecting the liver.
Keep Reading →
July 10 - News
We as a country have a come a long way over the past two decades with regard to treating HIV and reducing the number of AIDS diagnoses.
Keep Reading →
July 8 - News
For the second day in a row, the hot topic in the market is the bidding war for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX). After rejecting Amgen, Inc.
Keep Reading →
July 3 - News
Recently, Amgen, Inc. (NASDAQ:AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).
Keep Reading →
July 3 - News
AbbVie Inc (NYSE:ABBV) has risen more than 20% since it hit the market earlier this year. In fact, it has managed to beat the S&P 500 by nearly 10%.
Keep Reading →
July 1 - News
Stock price movements reflect investors' opinions about a company's worth; upward moves attracts investor interest because they indicates good performance.
Keep Reading →
July 1 - News
To prove my point, I looked at the multi-year chart and picked out some of the peaks.
Keep Reading →
July 1 - News
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) just can't catch a break.
Keep Reading →
June 28 - News
Biotech companies sometimes get lucky, launching a drug into a new indication where there's no competition, but more often than not the biotech companies have to battle it out...
Keep Reading →
June 27 - News
Global equity markets have been rocked recently as fears of rising interest rates and tightening monetary possible make their way into the minds of the street.
Keep Reading →
June 26 - News
Dividend stocks are hard to come by in the biotech space.
Keep Reading →
June 26 - News
Investing in biotech companies can be risky; developing new drugs is a long, expensive, and uncertain process, and there is always considerable regulatory risk in the industry...
Keep Reading →
June 26 - News
For investors viewing AbbVie Inc (NYSE:ABBV) as a value play since its spin-off from Abbott Laboratories (NYSE:ABT), it is time to think again.
Keep Reading →
June 26 - News
Earnings Per Share (EPS) growth is one measure of a company's profitability. Since it is often the most commonly discussed performance metric, it tends to drive share prices.
Keep Reading →
June 25 - News
Hepatitis-C is a contagious virus that attacks the liver and can be found in acute or chronic forms.
Keep Reading →
June 24 - News
Gilead Sciences, Inc. (NASDAQ:GILD) has been one of the most prolific investments in the healthcare sector.
Keep Reading →
June 18 - News
